Evidence map›Paper›PMID 38725998›Full record

ArticleFrontiers in immunology2024

Group 2 innate lymphoid cells are key in lipid transfer protein allergy pathogenesis.

Francisca Palomares, Natalia Pérez-Sánchez, Nazaret Nieto, Rafael Núñez, José Antonio Cañas, María Del Carmen Martín-Astorga, Anyith Cruz-Amaya, María José Torres, Ibon Eguíluz-Gracia, Cristobalina Mayorga and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Francisca PalomaresAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
Natalia Pérez-SánchezAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
Nazaret NietoAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
Rafael NúñezAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
José Antonio CañasAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
María Del Carmen Martín-AstorgaAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
Anyith Cruz-AmayaAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
María José TorresAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
Ibon Eguíluz-GraciaAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
Cristobalina MayorgaAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.
Francisca GómezAllergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA Plataforma Andalusian Centre for Nanomedicine and Biotechnology (BIONAND), Málaga, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immunopathology in food allergy is characterized by an uncontrolled type 2 immune response and specific-IgE production. Recent studies have determined that group 2 innate lymphoid cells (ILC2) participate in the food allergy pathogenic mechanism and their severity. Our objective was to investigate the role of ILC2 in peach-allergic patients due to non-specific lipid transfer protein (Pru p 3) sensitization. Methods: The immune response in peripheral blood mononuclear cells was characterized in lipid transfer protein-allergic patients and healthy controls. We have analyzed the Pru p 3 uptake on ILC2, the expression of costimulatory molecules, and their involvement on the T-cell proliferative response and cytokine production under different experimental conditions: cytokines involved in group 2 innate lymphoid cell activation (IL-33 and IL-25), Pru p 3 as main food allergen, and the combination of both components (IL-33/IL-25+Pru p 3) using cell sorting, EliSpot, flow cytometry, and confocal microscopy. Results: Our results show that Pru p 3 allergen is taken up by group 2 innate lymphoid cells, regulating their costimulatory molecule expression (CD83 and HLA-DR) depending on the presence of Pru p 3 and its combination with IL-33/IL-25. The Pru p 3-stimulated ILC2 induced specific GATA3 Conclusions: The results indicate that in lipid transfer protein-allergic patients, the responsible allergen, Pru p 3, interacts with group 2 innate lymphoid cells, promoting a Th2 cell response. Our results might be of interest

Indexed as

Antigens, PlantCarrier ProteinsFood HypersensitivityImmunity, InnateAdultCytokinesFemaleHumansLymphocyte ActivationLymphocytesMaleMiddle AgedPlant ProteinsYoung AdultAntigens, PlantCarrier ProteinsCytokineslipid transfer proteinPlant ProteinsPru p 3 allergenantigen-presenting cellsfood allergyinnate lymphoid cellslipid transfers proteinsTh2-cellstype 2 immune response

Identifiers

PMID38725998
PMCPMC11079275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.